TRAVERE THERAPEUTICS

Lobbying client · California · filed 2025 to 2025

Biopharmaceutical company

$12,000 Reported spend

1 Filings counted

1 Firms hired

1 Bills named

Spend is reported income plus in-house expenses across 1 filing. Everything on this page is grouped by the client's LDA id (212318), not by name.

Firms hired 1

2359 STRATEGIES $12,000 1 filing

Bills named in these filings 1

HR 1518
New Era of Preventing End-Stage Kidney Disease Act

1 filing

Reported by year 1 year

2025 $12,000 1 filing

Issues lobbied 5

The count is how many filings named that issue area. A filing reports one lump figure covering every issue on it, so the money above cannot be split between them.

Agencies and chambers lobbied 2

HOUSE OF REPRESENTATIVES 1
SENATE 1

Recent filings 1 total

Q1

2359 STRATEGIES

1st Quarter (Jan 1 - Mar 31) 2025 · House · Senate · $12,000 income · posted Apr 19, 2025

View →

Source: federal Lobbying Disclosure Act filings, synced daily. Money is self-reported by the filer and often rounded. Lobbying is legal, disclosed activity.